| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | US14246519 | 2014-04-07 | US20140294762A1 | 2014-10-02 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David James Hakes; Caryn L. Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
| 122 | Devices for controlling magnetic nanoparticles to treat fluid obstructions | US13505447 | 2010-11-02 | US08715150B2 | 2014-05-06 | Francis M. Creighton |
| The present invention relates to a system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator. In one aspect, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels. | ||||||
| 123 | Magnetic-based methods for treating vessel obstructions | US13471908 | 2012-05-15 | US08313422B2 | 2012-11-20 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 124 | MAGNETIC-BASED METHODS FOR TREATING VESSEL OBSTRUCTIONS | US13471908 | 2012-05-15 | US20120232329A1 | 2012-09-13 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 125 | MAGNETIC-BASED SYSTEMS FOR TREATING OCCLUDED VESSELS | US13471871 | 2012-05-15 | US20120226093A1 | 2012-09-06 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 126 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | US13246512 | 2011-09-27 | US20120220517A1 | 2012-08-30 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David James Hakes; Caryn Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
| 127 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | US13178835 | 2011-07-08 | US20120027687A1 | 2012-02-02 | Daniel L. Alkon |
| The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C(PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke. | ||||||
| 128 | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | US10021508 | 2001-10-22 | US06602975B2 | 2003-08-05 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Jennifer L. Hill |
| Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces. | ||||||
| 129 | Gels for encapsulation of biological materials | US09910663 | 2001-07-19 | US20030087985A1 | 2003-05-08 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Syed F.A. Hossainy; Jennifer L. Hill-West |
| This invention provides novel methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a nullgluenull to cause more than one biological substance to adhere together, or as carriers for biologically active species. Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species which are at once polymers and macromolecules capable of further polymerization. The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization. The polymer membrane can be formed directly on the surface of the biological material, or it can be formed on material which is already encapsulated. | ||||||
| 130 | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | US128917 | 1998-08-04 | US6060582A | 2000-05-09 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Jennifer L. Hill-West |
| Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces. | ||||||
| 131 | Genetic modification of endothelial cells | US488420 | 1995-06-07 | US6001350A | 1999-12-14 | Richard C. Mulligan; Lawrence K. Cohen; Louis K. Birinyi; James M. Wilson |
| Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual. | ||||||
| 132 | Thrombosis agent | US410766 | 1995-03-27 | US5776452A | 1998-07-07 | Johann Eibl; Anton Philapitsch; Hans Peter Schwarz |
| The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also provides simple and safe therapies for thrombotic states and prevention of such states. | ||||||
| 133 | Thrombolytic composition | US750711 | 1997-03-18 | US5741771A | 1998-04-21 | Keith Martyn Dawson; Lars Michael Wood; Michael Berisford Comer |
| The invention disclosed relates to thrombolytic combination therapy by the administration of an agent capable of activating native plasminogen, and a non-native plasminogen analogue which is cleavable by native thrombin to generate plasmin activity. | ||||||
| 134 | Methods for thrombolytic therapy | US517915 | 1990-04-02 | US5188830A | 1993-02-23 | Joseph G. Atkinson; David A. Claremon; John J. Baldwin; Paul A. Friedman; David C. Remy; Andrew M. Stern |
| Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator. | ||||||
| 135 | Automatic injector for emergency treatment | US228536 | 1988-08-05 | US5078680A | 1992-01-07 | Stanley Sarnoff |
| A method of treating a patient with liquid medicament under circumstances where intravenous injection is not practical but the fast response time of an intravenous injection is desirable, including the treatment of individuals undergoing heart attack symptoms with t-PA. The method comprises the steps of injecting the liquid medicament t-PA preferably with a blood absorption enhancing agent such as hydroxylamine hydrochloride into the muscle tissue of the patient, applying to the patient which has received the injection repeated blood flow stimulating cycles, each of which includes a period of electrical stimulus during which the muscle tissue which has received the injection tenses followed by a period of no electrical stimulus during which the muscle tissue which received the injection is allowed to relax inducing enhanced blood flow within the muscle tissue, and continuing the application of the repeated blood flow stimulating cycles until the injected liquid medicament has been sufficiently absorbed into the enhanced blood flow to achieve a desired possible patient response of reperfusion and apparatus for carrying out the method. | ||||||
| 136 | SYNTHETIC PLATELETS | US15968062 | 2018-05-01 | US20180311378A1 | 2018-11-01 | Samir Mitragotri; Apoorva Sarode; Yongsheng Gao |
| Provided herein are various functionalized particles comprising a shell, dendritic linkers, and functional moieties. The dendrimer linkers allow very large numbers of functional moieties to be bound to the shell. The functional moieties may comprise peptides which synergistically promote platelet aggregation and hemostasis in wounded tissues. The functionalized particles may further be effectors of wound healing, thrombolysis and other functions, depending on the selection of functional moiety. Functionalized polymers having these functions are provided as well. | ||||||
| 137 | Steroidal nitrones for the treatment and prevention of a cerebral stroke or ischaemia, alzheimer and parkinson disease and amyotrophic lateral sclerosis | US14892755 | 2014-05-22 | US10071106B2 | 2018-09-11 | José Luis Marco Contelles; Alberto Alcázar González |
| The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis. | ||||||
| 138 | Aminofucoidan as a vector for fibrinolysis in thrombotic diseases | US14778259 | 2014-03-21 | US09999679B2 | 2018-06-19 | Stephane Loyau; Martine Jandrot-Perrus; Didier Letourneur; Frederic Chaubet; Benoit Ho-Tin-Noe; Murielle Maire; Jean-Baptiste Michel |
| The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety. | ||||||
| 139 | Pharmaceutical compositions of tenecteplase | US15136614 | 2016-04-22 | US09943575B2 | 2018-04-17 | Maheshwari Kumar Mishra; Pritiranjan Bhandari; Sanjay Singh |
| Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke. | ||||||
| 140 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION | US15456146 | 2017-03-10 | US20170285034A1 | 2017-10-05 | Farhad Kosari; George Vasmatzis; Marie-Christine Aubry; Cristiane M. Ida |
| This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided. | ||||||
QQ群二维码
意见反馈
意见反馈